Medicina
Departamento
Novartis (Sweden)
Täby, SueciaPublicaciones en colaboración con investigadores/as de Novartis (Sweden) (4)
2014
-
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: An open-label, randomised phase 3 trial
The Lancet Oncology, Vol. 15, Núm. 3, pp. 286-296
2009
-
Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: Sub-analysis of a 52-week, randomized, double-blind trial
Journal of Hypertension, Vol. 27, Núm. 7, pp. 1493-1501
-
Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone
Journal of Clinical Hypertension, Vol. 11, Núm. 6, pp. 324-332
-
Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren. A 12-month randomized, double-blind comparator trial with hydrochlorothiazide
Circulation, Vol. 119, Núm. 3, pp. 417-425